Robert Croop

Featured in: Favicon

thelancet.com Favicon

dovepress.com Favicon

Articles

Efficacy of rimegepant 75 mg oral tablet for migraine

Dec 18, 2023 | dovepress.com | Richard Lipton |Alexandra Thiry |Beth Morris |Robert Croop

Back to Journals » Journal of Pain Research » Volume 17 Original ResearchHeadache and Facial Pain Authors Lipton RB, Thiry A, Morris BA, Croop R Received 18 December 2023Accepted for publication 8 July 2024 Published 22 July 2024Volume 2024:17 Pages 2431—2441 DOI https://doi.org/10.2147/JPR.S453806Checked for plagiarism YesReview by Single anonymous peer reviewPeer reviewer comments 4 Editor who approved publication: Prof.
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

Feb 16, 2023 | thelancet.com | Richard Lipton |Albert Einstein College |Bronx NY |Robert Croop

Background Intranasal formulations can provide treatment options for people with migraine in whom oral drugs are ineffective, slow-acting, or intolerable because of nausea and vomiting. Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phase 2/3 trial.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →